.Attributes Medicine, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) therapy of people with HER2+ advanced breast cancer and active or dependable brain metastases presented constant intracranial task and systemic effectiveness of T-DXd.